Introduction

Biologics are forecast to be the fastest growing segment of the pharmaceutical market out to 2010 (12.2% CAGR). However, biologics face the emergence of bio-similars and increasing numbers of competitor products, both factors that intensify the commercial need for next-generation biologics with superior product characteristics. DMEa method for optimizing biologicsdirectly addresses this need.

Scope

• Assessment of the DME total market opportunity using global sales forecasts for all biologics, split by company and therapy area, spanning 200110
• Classification system for understanding DME technologies decomposing the process into diversification, selection and protein format steps
• Detailed company analysis of both AME and Maxygen in terms of corporate history, internal pipeline, alliance networks and financial performance
• Analysis of how companies such as MorphoSys and CAT are using 'display systems' to accelerate the DME process in drug discovery

Highlights

Alliance network maps revealing which pharmaceutical players are accessing DME through product technology collaborations with AME and Maxygen including an analysis of how Eli Lilly's 2004 acquisition of AME redefined the DME competitive landscape.

Case study of how MedImmune applied DME to its marketed anti-RSV monoclonal antibody Synagis to create the next-generation product Numax, which is forecast to produce global sales in excess of $1bn by 2010.

Review of the major DME technologies which are in use with a consideration of their relative strengths and weaknesses and suitability for different commercial applications.

Reasons to Purchase

• Learn how DME opens up a route to generating highly optimized versions of currently marketed biologics and vaccines
• Understand how DME can be applied in the discovery and development process to enhance the binding affinity and stability of biologic lead candidates
• Identify the key holders of DME technology, how to gain access to this powerful method and which techniques are best suited to which biomolecule types.
• http://www.bioportfolio.com/cgi-bin/acatalog/Directed_Molecular_Evolution__Product_lifecycle_ma.html

To order Directed Molecular Evolution: Product lifecycle management for biologics contact peter.barfoot@bioportfolio.com or telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back to you.

You can also order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html